Celebrex On The “Rebound,” Pfizer Says
Celebrex has nearly regained the market share it lost during the COX-2 inhibitor safety controversy, Pfizer said Jan. 19
Celebrex has nearly regained the market share it lost during the COX-2 inhibitor safety controversy, Pfizer said Jan. 19